Thompson Siegel & Walmsley LLC Takes Position in Myomo, Inc. (NYSEAMERICAN:MYO)

Thompson Siegel & Walmsley LLC acquired a new stake in Myomo, Inc. (NYSEAMERICAN:MYO) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 200,000 shares of the company’s stock, valued at approximately $1,288,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MYO. Barclays PLC bought a new position in Myomo in the third quarter valued at approximately $36,000. Jane Street Group LLC bought a new position in Myomo in the third quarter valued at approximately $65,000. XTX Topco Ltd bought a new position in Myomo in the third quarter valued at approximately $149,000. Thompson Davis & CO. Inc. bought a new position in Myomo in the fourth quarter valued at approximately $181,000. Finally, Calamos Advisors LLC bought a new position in Myomo in the fourth quarter valued at approximately $189,000. 44.99% of the stock is owned by institutional investors.

Myomo Trading Up 2.4 %

Shares of NYSEAMERICAN:MYO opened at $5.19 on Friday. Myomo, Inc. has a 12 month low of $2.51 and a 12 month high of $7.17. The firm has a market cap of $157.00 million, a P/E ratio of -22.57 and a beta of 1.68.

Insider Buying and Selling

In other Myomo news, insider Micah Mitchell sold 48,000 shares of Myomo stock in a transaction on Friday, March 14th. The shares were sold at an average price of $5.16, for a total value of $247,680.00. Following the sale, the insider now directly owns 140,572 shares in the company, valued at approximately $725,351.52. The trade was a 25.45 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Thomas F. Kirk purchased 7,400 shares of the stock in a transaction on Thursday, March 13th. The stock was acquired at an average price of $5.00 per share, for a total transaction of $37,000.00. Following the completion of the purchase, the director now directly owns 255,933 shares in the company, valued at approximately $1,279,665. The trade was a 2.98 % increase in their position. The disclosure for this purchase can be found here. 4.54% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on MYO shares. HC Wainwright lifted their price target on shares of Myomo from $7.50 to $9.50 and gave the stock a “buy” rating in a research report on Wednesday. Alliance Global Partners reissued a “buy” rating on shares of Myomo in a research report on Tuesday. Finally, Craig Hallum lifted their price target on shares of Myomo from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $9.25.

Myomo Company Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.